OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html

Syndivia receives the EU’s Horizon 2020 grant

The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.

Meet us at the SMi's annual ADC Summit

May 23-24, Syndivia's CEO will be giving a talk at the SMi's annual ADC Summit in London.
The topics covered in the talk will include:
•    New ADC linkers with increased serum stability
•    Next-generation DM1- and MMAE-based payloads
•    Expanding the scope of ADC targets by fine-tuning the drug release properties
For more information, visit the website of the conference:
https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit
 

Publication in Bioconjugate Chemistry

Syndivia introduces a first-in-class reagent for kinetically resolved thiol-to-thiol conjugation in its recent publication in Bioconjugate Chemistry. The MAPN reagent allows for the preparation of stable Antibody-Drug Conjugates through conjugation of thiol-containing drugs to the cysteine residues of the antibody.
The publication can be downloaded on the ACS website: http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.5b00440

Syndivia lands €275k grant to develop next-generation targeted cancer therapies

Syndivia was nominated laureate of the i-LAB 2015 in the category "création-développement". i-LAB is a nationwide contest of innovative companies supported by the French Ministry of Higher Education and Research. The prize includes €275k financial support for Syndivia's R&D program on the development of next-generation targeted cancer therapies.